|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-4-9
|
|
pubmed:abstractText |
Few therapeutic options are presently available for patients with multiple myeloma (MM) who relapse after autologous or allogeneic stem cell transplantation, or for patients who are refractory to conventional chemotherapy and not eligible for salvage high-dose therapy. Thalidomide, a glutamic acid derivative with anti-angiogenic properties, has been recently proposed as an effective therapy for patients with advanced refractory disease. The aim of this study was to evaluate the activity of thalidomide in a large series of MM patients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
pubmed-author:BaccaraniMicheleM,
pubmed-author:BalleriniFilippoF,
pubmed-author:CanginiDeliaD,
pubmed-author:CavoMicheleM,
pubmed-author:CelliniClaudiaC,
pubmed-author:Di RaimondoFrancescoF,
pubmed-author:GobbiMarcoM,
pubmed-author:LauriaFrancescoF,
pubmed-author:LeddaAntonioA,
pubmed-author:MasiniLucianoL,
pubmed-author:MeugnierMM,
pubmed-author:MustoPellegrinoP,
pubmed-author:RiaRobertoR,
pubmed-author:RonconiSoniaS,
pubmed-author:TosiPatriziaP,
pubmed-author:TuraSanteS,
pubmed-author:VaccaAngeloA,
pubmed-author:ZamagniElenaE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
87
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
408-14
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11940485-Adult,
pubmed-meshheading:11940485-Aged,
pubmed-meshheading:11940485-Biological Markers,
pubmed-meshheading:11940485-Bone Marrow Cells,
pubmed-meshheading:11940485-Cell Culture Techniques,
pubmed-meshheading:11940485-Endothelial Growth Factors,
pubmed-meshheading:11940485-Female,
pubmed-meshheading:11940485-Humans,
pubmed-meshheading:11940485-Lymphokines,
pubmed-meshheading:11940485-Male,
pubmed-meshheading:11940485-Maximum Tolerated Dose,
pubmed-meshheading:11940485-Middle Aged,
pubmed-meshheading:11940485-Multiple Myeloma,
pubmed-meshheading:11940485-Prognosis,
pubmed-meshheading:11940485-Salvage Therapy,
pubmed-meshheading:11940485-Thalidomide,
pubmed-meshheading:11940485-Vascular Endothelial Growth Factor A,
pubmed-meshheading:11940485-Vascular Endothelial Growth Factors
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
|
|
pubmed:affiliation |
Istituto di Ematologia e Oncologia Medica "L. e A. Seràgnoli", Policlinico S. Orsola, via Massarenti 9, 40138 Bologna, Italy. ptosi@med.unibo.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
